BNET Industries

Market Cap:$39.6M
Last Fiscal Year Sales:$168.4K
  • Public
  • US
Dow Jones Description

RegeneRx was formed in 1982 and is a pharmaceutical research and development company focusing on the development of products to treat a variety of human diseases. RegeneRx?s current primary business focus is the commercialization of Thymosin beta 4 (?T4?), a 43 amino acid peptide. RegeneRx is concentrating its efforts on developing a series of pharmaceutical products, based on T4, to accelerate healing and repair of diseased, damaged, and non-healing tissue and organs. Such products may also be useful in preventing damage under certain conditions. RegeneRx utilizes an outsourcing business strategy in order to effectively control costs while focusing on the clinical development of T4. RegeneRx uses this model for certain research and development, clinical trials, and manufacturing operations, as well as other functions critical to its mission. RegeneRx believes this approach enhances its ability to allocate resources rapidly to different projects. The strategy consists of (i) identifying, evaluating and licensing pharmaceutical product opportunities that appear to have a significant commercial potential; (ii) designing pre-clinical and/or clinical protocols to test such products; (iii) utilizing third party contract manufacturers to supply clinical grade material and third party contract research organizations to perform pre-clinical and/or clinical studies in accordance with its designed protocols; and (iv) pursuing sublicense arrangements with established pharmaceutical companies to support late stage clinical testing and ultimately marketing if regulatory approval is obtained.

Number of Employees 7
Contact Information

3 Bethesda Metro Center

Suite 700

Bethesda, Maryland 20814

regenerx.com

3019611992

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

Recent Events

  • BioWatch: Industry gears up for mid-Atlantic conference

    10/31/09 - New Investment - View Story

  • RegeneRx Biopharmaceuticals announces collaboration with USAMRICD

    6/24/09 - Joint Venture / Alliance - View Story

News & Analysis

regenerx biopharmaceuticals inc. - All News and Analysis

Decision Makers

Name (plus bio) Position
JJ Finkelstein President
Allan L Goldstein Chief
C Neil Lyons Chief Financial Officer and Treasurer
David Crockford Vice President, Clinical and Regulatory Affairs
Claudio Cavazza
Paolo Cavazza
Mauro Bove Director
Albert Rosenfeld Member

Board of Directors

Name (plus bio) Position
Richard J. Hindin Chairman
Barrett Katz Board of Directors
Deepak Srivastava Board of Directors
Ewald Hannappel Board of Directors
Gabriel Sosne Board of Directors
Herve Byron Board of Directors
Hynda K. Kleinman Board of Directors
Jo-David Fine Board of Directors
Joseph C. McNay Board of Directors
L Thompson Bowles Board of Directors
Paolo Carminati Board of Directors

Organization Position Status
Regenerx Biopharmaceuticals, Inc. President Current
Maryland Angels Council Director Current

Dr. Goldstein is Chairman of the Board of Directors and the Company's Chief Scientific Advisor. He is also a founder of the Company and Professor and Chairman of the Department of Biochemistry and Molecular Biology at the George Washington University School of Medicine and Health Sciences, a position he has held since 1978. Dr. Goldstein is a recognized expert in the field of immunology and protein chemistry. He is the discoverer of several important compounds, including T 1 and T 4. Dr. Goldstein has served on the editorial boards of numerous scientific and medical journals and is a member of the Board of Trustees of the Albert Sabin Vaccine Institute, the Institute for Advanced Studies in Aging and Geriatric Medicine, and the Richard B. and Lynne V. Chaney Cardiovascular Institute. Dr. Goldstein is also the author of more than 425 scientific articles and professional journals, the inventor on over fifteen U.S. patents, and the editor of several books in the field of biochemistry, biomedicine, immunology and neuroscience.

Organization Position Status
Regenerx Biopharmaceuticals, Inc. Chief Current
Irx Therapeutics, Inc. Current
Regenerx Biopharmaceuticals, Inc. Board of Directors Current
Lynne V. Cheney Cardiovascular Institute Board Member Current
Institute for Advanced Studies Board of Directors Current
Institute for Advanced Studies President Former
Regenerx Biopharmaceuticals, Inc. Founder Former
Institute for Advanced Studies Co-Founder Former
Institute for Advanced Studies Science Director Former
Regenerx Biopharmaceuticals, Inc. Advisor Former
Institute for Advanced Studies Consultant Former
University of Virginia School of Medicine Professor of Internal Medicine and Pathology Former
Supreme Court of the United States Former
Albert B. Sabin Vaccine Institute Professor and Chairman, Dept. of Biochemistry and Molecular Biology Former
Albert Einstein College Board of Directors Former
Stanford University MD Former
Rutgers University Ph.D. Former
Rutgers University M.S. Former
Wagner College B.S. Former

Organization Position Status
Regenerx Biopharmaceuticals, Inc. Chief Financial Officer and Treasurer Current
Skybridge Corporation Senior Financial Executive Current
Hfs, Inc. Senior Financial Executive Former
Florida Southern College Bachelor of Science Degree Former

Mr. Crockford is RegeneRx?s Vice President, Clinical and Regulatory Affairs. He has more than 25 years of experience in the biotechnology and pharmaceutical industries. During his career as a clinical and regulatory affairs professional, Mr. Crockford established strategic plans, implemented and obtained marketing approval for eighteen drug products, including one of the first human growth hormone preparations sold in the U.S., seventeen in vitro diagnostic tests, and an intraoperative medical device to detect and treat cancer. Other clinical and regulatory achievements credited to Mr. Crockford include the cost-effective and timely development of a number of innovative investigational drugs. Mr. Crockford has a number of publications and holds more than a dozen patents.

Organization Position Status
Regenerx Biopharmaceuticals, Inc. Vice President, Clinical and Regulatory Affairs Current

Organization Position Status
Regenerx Biopharmaceuticals, Inc. Current

Organization Position Status
Regenerx Biopharmaceuticals, Inc. Current

Mr. Hindin is a member of the Board of Directors, having been elected in 2002. He is President and CEO of Adworks Inc., a Washington, D.C. based advertising and marketing firm having revenues in excess of $80 million annually. He is also Founder of Chicken Out Rotisserie Inc., which operates 29 restaurants in four states and the District of Columbia, with annual sales in excess of $35 million. In 1967, he co-founded Britches of Georgetowne, Inc., a clothing retailer specializing in the sale of upscale men's and women's apparel and accessories. Under his stewardship as its President and CEO, Britches became a chain of 77 units in seven states with annual sales exceeding $120 million. Currently, Mr. Hindin serves as Chairman of the Board of The Institute of Advanced Studies in Immunology and Geriatric Medicine, a non-profit 501(c)(3) corporation that specializes in disseminating medical information to the public, as well as providing the pharmaceutical industry with an independent source for testing vaccines and drugs for the elderly.

Organization Position Status
ADWORKS, Inc. CEO Current
ADWORKS, Inc. President Current
District of Columbia, LLC Founder Current
Institute for Advanced Studies Chairman of the Board of Directors Current
Institute of Advanced Studies Chairman of the Board Current
Regenerx Biopharmaceuticals, Inc. Chairman Current
District of Columbia, LLC Director Current
Regenerx Biopharmaceuticals, Inc. Director Former

Organization Position Status
Regenerx Biopharmaceuticals, Inc. Board of Directors Current

Organization Position Status
Regenerx Biopharmaceuticals, Inc. Board of Directors Current

Organization Position Status
Regenerx Biopharmaceuticals, Inc. Board of Directors Current

Organization Position Status
Regenerx Biopharmaceuticals, Inc. Board of Directors Current

Organization Position Status
Regenerx Biopharmaceuticals, Inc. Board of Directors Current

Organization Position Status
Regenerx Biopharmaceuticals, Inc. Board of Directors Current

Organization Position Status
Regenerx Biopharmaceuticals, Inc. Board of Directors Current

Organization Position Status
Essex Investment Management Company, LLC Chief Investment Officer Current
Essex Investment Management Company, LLC Chairman Current
M.P.S.I., Inc. Board of Directors Current
Boston Ballet Inc. Board of Directors Current
Simmons College Board of Trustees Current
Regenerx Biopharmaceuticals, Inc. Board of Directors Current
The Boston Security Analysts Society, Inc Board of Directors Current
The Overseer Board of Directors Current
National Public Radio Inc. Board of Directors Current
Children's Hospital Board of Directors Current
National Public Radio Inc. Trustee Current
Wharton Investment Management Conference Chairman, CIO & Managing Principal, Essex Investment Management Current
Massachusetts, Inc. Senior Portfolio Manager Former
Essex Investment Management Company, LLC Managing Principal Former
Wharton Graduate School of the University of Pennsylvania M.B.A. Former
Yale University A.B. Degree Former

Organization Position Status
Regenerx Biopharmaceuticals, Inc. Board of Directors Current
New York University Ph.D. Former
Duke University Degree Former

Organization Position Status
Regenerx Biopharmaceuticals, Inc. Director Current
Sigma Tau Former

Organization Position Status
Regenerx Biopharmaceuticals, Inc. Board of Directors Current

In 2006, Mr. Rosenfeld became an emeritus member of RegeneRx?s Board of Directors, having served on the Board since the Company?s founding in 1982. Previously, he was the former science editor of Life magazine and Saturday Review, Consultant on Future Programs for the March of Dimes Birth Defects Foundation, and an adjunct professor in the Department of Human Biological Chemistry and Genetics at the University of Texas Medical Branch, Galveston, Texas. He has received many writing awards, including the Lasker Award, with a special citation for "leadership in medical journalism," and is a frequent author and lecturer on scientific matters.

Organization Position Status
Regenerx Biopharmaceuticals, Inc. Member Current
Regenerx Biopharmaceuticals, Inc. Board of Directors Current
The Review Company Former
advertisement
     RGN $0.64 -0.04 (-5.56% )
Average Volume 171,353
Shares Outstanding 60.41M
Market Cap 38.8M
Year High 1.95
Year Low 0.31
Earnings Per Share -0.15
P/E Ratio -4.28
Dividend N/A
Yield N/A
advertisement